Facioscapulohumeral Muscular Dystrophy (FSHD)
Conditions
Brief summary
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).
Interventions
DRUGPlacebo
Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
DRUGRO7204239
Participants will receive SC RO7204239 Q4W
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Genetic confirmation of FSHD1 or FSHD2 * Clinical findings consistent with FSHD * Ability to walk unassisted * Ricci Clinical Severity Scale score ≥ 2.5 and ≤ 4 * Agreement to maintain the same frequency and intensity of physiotherapy, occupational therapy, and other forms of exercise during the clinical study
Exclusion criteria
* Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 17 months after the final dose of RO7204239 * Current or previous treatment (or receipt) of anti-myostatin therapies * Treatment with any investigational therapy within 90 days prior to screening, or 5 drug-elimination half-lives of the drug, whichever is longer * Contraindications to MRI scans * Presence of clinically significant ECG abnormalities * Presence of clinically significant cardiovascular disease * Presence of clinically significant abnormal findings in echocardiography at screening, with the exception of mitral valve prolapse, which does not exclude participants from the study * Any major illness within 1 month before screening * Ascertained or presumptive hypersensitivity (e.g., anaphylactic reaction) to RO7204239, or to the constituents of its formulation * History of malignancy (except in situ basal cell carcinoma of the skin and in situ carcinoma of the cervix of the uterus that have been excised and resolved with documented clean margins on pathology) * Any clinically relevant history of anaphylactic reaction requiring inotropic support * Any abnormal skin conditions, pigmentation, or lesions in the area intended for SC injection (abdomen) and that would prevent visualization of potential injection-site reactions to RO7204239 * Immobilization, surgical procedures, fracture, or trauma to the upper or lower limbs within 90 days prior to screening or longer, if judged by the investigator that it may affect motor function assessment * Any planned surgery that may affect a participant's motor function assessment, including participants who have had surgery of scapular fixation within the 12 months preceding screening or that are planned during the study * Use of the following medications within 90 days prior to enrollment: salbutamol or another β2-adrenergic agonist taken orally; creatine; recombinant human growth hormone; recombinant human insulin growth factor-1; testosterone, oxandrolone, or other anabolic steroid; chronic oral or parenteral use of corticosteroids (inhaled corticosteroid use is allowed) unless required to manage injection reactions;agents anticipated to increase or decrease muscle volume or strength
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change from baseline in contractile muscle volume (CMV) of quadriceps femoris muscles as assessed by magnetic resonance imaging (MRI) bilaterally | Week 52 |
| Percentage of participants with adverse events (AEs) | Up to 2.5 years |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in serum concentration of total latent myostatin | Through 2 years |
| Change from baseline in serum concentration of free latent myostatin | Through 2 years |
| Change from baseline in serum concentration of mature myostatin | Through 2 years |
| Percent change from baseline in CMV of 36 muscles based on whole body MRI | Weeks 28 and 52 |
| Change from baseline in fat fraction of 36 muscles based on whole body MRI | Weeks 28 and 52 |
| Percent change from baseline in CMV of quadriceps femoris muscles as assessed by MRI bilaterally | Week 28 |
| Change from baseline in fat fraction of quadriceps femoris muscles as assessed by MRI bilaterally | Weeks 28 and 52 |
| Percent change from baseline in CMV of tibialis anterior muscles as assessed by MRI bilaterally | Weeks 28 and 52 |
| Change from baseline in fat fraction of tibialis anterior muscles as assessed by MRI bilaterally | Weeks 28 and 52 |
| Percent change from baseline in CMV of biceps brachii muscles as assessed by MRI bilaterally | Weeks 28 and 52 |
| Change from baseline in fat fraction of biceps brachii muscles as assessed by MRI bilaterally | Weeks 28 and 52 |
| Percent change from baseline in contractile cross-sectional area (CSA) of skeletal muscle in the proximal lower limb muscles as assessed by MRI bilaterally | Weeks 28 and 52 |
| Change from baseline in fat fraction of proximal lower limb muscles as assessed at a single mid-femur slice bilaterally by MRI | Weeks 28 and 52 |
| Serum concentration of RO7204239 | Through 2 years |
| Maximum serum concentration (Cmax) of RO7204239 | Through 2 years |
| Area under the concentration-time curve (AUC) of RO7204239 | Through 2 years |
| Trough concentration (Ctrough) of RO7204239 | Through 2 years |
| Percentage of participants with anti-drug antibodies (ADAs) | Baseline up to approximately 2 years |
Countries
Denmark, Italy, United Kingdom, United States
Contacts
STUDY_DIRECTORClinical Trials
Hoffmann-La Roche
Outcome results
None listed